Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» Daiichi Sankyo
Daiichi Sankyo
Daiichi exits combo vaccine pact with Sanofi after pertussis shot manufacturing glitches
Daiichi exits combo vaccine pact with Sanofi after pertussis shot manufacturing glitches
Fierce Pharma
Daiichi Sankyo
Sanofi
vaccines
VN-0105
pertussis
drug manufacturing
Flag link:
Daiichi takes mRNA COVID-19 vaccine into clinic as Japanese R&D belatedly fires up
Daiichi takes mRNA COVID-19 vaccine into clinic as Japanese R&D belatedly fires up
Fierce Biotech
Daiichi Sankyo
MRNA
COVID-19
vaccines
Japan
Flag link:
AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication
AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication
Pharmaforum
AstraZeneca
Daiichi Sankyo
stomach cancer
Enhertu
Roche
Herceptin
Flag link:
Sanofi inks COVID-19 mRNA vaccine deal with Translate BioDaiichi Sankyo’s Mirogabalin Displays Significant Reduction in Post-SCI Neuropathic Pain
Sanofi inks COVID-19 mRNA vaccine deal with Translate BioDaiichi Sankyo’s Mirogabalin Displays Significant Reduction in Post-SCI Neuropathic Pain
BioSpace
Daiichi Sankyo
gabapentinoid
central neuropathic pain after spinal cord injury
spinal cord injury
Flag link:
Daiichi Sankyo takes oncology shift into next phase with new global business unit
Daiichi Sankyo takes oncology shift into next phase with new global business unit
Fierce Pharma
Daiichi Sankyo
oncology
Flag link:
Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer
Enhertu picks up another win for AstraZeneca and Daiichi Sankyo, joining the priority review lane for gastric cancer
Endpoints
AstraZeneca
Daiichi Sankyo
Enhertu
breakthrough status
FDA
metastatic gastric cancer
gastric cancer
Flag link:
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC
Daiichi Sankyo, AstraZeneca collaborate to evaluate patritumab deruxtecan in combination with TAGRISSO in EGFR-mutated NSCLC
Pharmaceutical Business Review
Daiichi Sankyo
AstraZeneca
patritumab deruxtecan
Tagrisso
non-small cell lung cancer
clinical trials
Flag link:
4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
4 Reasons AstraZeneca Gave Daiichi Sankyo Another $1 Billion Upfront
Motley Fool
AstraZeneca
DS-1062
Daiichi Sankyo
Flag link:
AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo
AstraZeneca inks $6bn cancer drug deal with Daiichi Sankyo
Pharmaforum
AstraZeneca
Daiichi Sankyo
DS-1062
antibodies
cancer
Flag link:
Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer
Daiichi Sankyo expands DS-1062 study to include patients with triple negative breast cancer
Pharmaceutical Business Review
Daiichi Sankyo
antibody-drug conjugate
triple negative breast cancer
DS-1062
clinical trials
Flag link:
AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful
AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful
Fierce Pharma
AstraZeneca
Daiichi Sankyo
University of Oxford
vaccines
COVID-19
Japan
Flag link:
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
Daiichi Sankyo and Thermo Fisher Partner on Companion Diagnostic Device for NSCLC
BioSpace
Daiichi Sankyo
Thermo Fisher
companion diagnostics
diagnostics
non-small cell lung cancer
Flag link:
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers
ASCO data back AZ/Daiichi Sankyo’s Enhertu in new HER2 cancers
Pharmaforum
Daiichi Sankyo
AstraZeneca
Enhertu
stomach cancer
colorectal cancer
lung cancer
ASCO 2020
Flag link:
AZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a week
AZ/Daiichi’s Enhertu gains second ‘breakthrough’ tag in space of a week
Pharmaforum
AstraZeneca
Daiichi Sankyo
Enhertus
metastatic non-small-cell lung cancer
Flag link:
AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug
AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug
Pharmaceutical Business Review
AstraZeneca
Daiichi Sankyo
FDA
Enhertu
gastric cancer
breakthrough therapy
Flag link:
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Daiichi Sankyo submits application for CAR T therapy axicabtagene ciloleucel to treat patients with certain relapsed/refractory B-cell lymphomas in Japan
Pharmaceutical Business Review
Daiichi Sankyo
Japan
CAR-T
axicabtagene ciloleucel
relapsed or refractory diffuse large B-cell lymphoma
Flag link:
Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer
Astra, Daiichi's Enhertu shows early promise in HER2 lung cancer
Fierce Biotech
AstraZeneca
Daiichi Sankyo
Enhertu
clinical trials
HER2-positive non-small cell lung cancer
Flag link:
AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch
AZ, Daiichi’s new cancer drug Enhertu gets off to the races with quick U.S. launch
Fierce Pharma
AstraZeneca
Daiichi Sankyo
clinical trials
FDA
Enhertu
cancer
breast cancer
Flag link:
Antibody-drug conjugates on the march
Antibody-drug conjugates on the march
Pharmaforum
antibody-drug conjugate
AstraZeneca
Daiichi Sankyo
Enhertu
Flag link:
Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study
Breast cancer approval in tow, AstraZeneca, Daiichi armed antibody scores in key gastric cancer study
Endpoints
AstraZeneca
breast cancer
Daiichi Sankyo
trastuzumab deruxtecan
gastric cancer
Flag link:
Pages
1
2
3
4
5
6
7
8
9
next ›
last »